JP2005523293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523293A5 JP2005523293A5 JP2003570883A JP2003570883A JP2005523293A5 JP 2005523293 A5 JP2005523293 A5 JP 2005523293A5 JP 2003570883 A JP2003570883 A JP 2003570883A JP 2003570883 A JP2003570883 A JP 2003570883A JP 2005523293 A5 JP2005523293 A5 JP 2005523293A5
- Authority
- JP
- Japan
- Prior art keywords
- water
- cellulose ether
- soluble cellulose
- pharmaceutical composition
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920003086 cellulose ether Polymers 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 10
- 150000002148 esters Chemical class 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000000080 wetting agent Substances 0.000 claims 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical group 0.000 claims 1
- 150000008051 alkyl sulfates Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-L isophthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC(C([O-])=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-L 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000003605 opacifier Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 claims 1
- 229940071117 starch glycolate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0204392A GB0204392D0 (en) | 2002-02-26 | 2002-02-26 | Pharmaceutical compound |
| GB0212462A GB0212462D0 (en) | 2002-05-30 | 2002-05-30 | Pharmaceutical compound |
| GB0213267A GB0213267D0 (en) | 2002-06-11 | 2002-06-11 | Pharmaceutical composition |
| PCT/GB2003/000803 WO2003072139A1 (en) | 2002-02-26 | 2003-02-24 | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523293A JP2005523293A (ja) | 2005-08-04 |
| JP2005523293A5 true JP2005523293A5 (https=) | 2006-03-09 |
| JP4544863B2 JP4544863B2 (ja) | 2010-09-15 |
Family
ID=27767732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003570883A Expired - Lifetime JP4544863B2 (ja) | 2002-02-26 | 2003-02-24 | 水溶性セルロース誘導体を含むイレッサの医薬製剤 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20050163835A1 (https=) |
| EP (1) | EP1480679B1 (https=) |
| JP (1) | JP4544863B2 (https=) |
| KR (2) | KR20100090726A (https=) |
| CN (1) | CN1326569C (https=) |
| AR (1) | AR038848A1 (https=) |
| AT (1) | ATE362771T1 (https=) |
| AU (1) | AU2003208444B2 (https=) |
| BR (1) | BRPI0307786B8 (https=) |
| CA (1) | CA2476587C (https=) |
| CO (1) | CO5601038A2 (https=) |
| CY (1) | CY1108026T1 (https=) |
| DE (1) | DE60313956T2 (https=) |
| DK (1) | DK1480679T3 (https=) |
| ES (1) | ES2286406T3 (https=) |
| IL (2) | IL163642A0 (https=) |
| IS (1) | IS2462B (https=) |
| MX (1) | MXPA04008307A (https=) |
| MY (1) | MY135609A (https=) |
| NO (1) | NO328658B1 (https=) |
| NZ (1) | NZ534513A (https=) |
| PL (1) | PL208114B1 (https=) |
| PT (1) | PT1480679E (https=) |
| RU (1) | RU2318518C2 (https=) |
| SA (1) | SA03240043B1 (https=) |
| TW (1) | TWI271193B (https=) |
| UA (1) | UA76325C2 (https=) |
| UY (1) | UY27682A1 (https=) |
| WO (1) | WO2003072139A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2342660T3 (es) | 2002-02-26 | 2010-07-12 | Astrazeneca Ab | Nuevas formas cristalinas del compuesto anticancerigeno zd1839. |
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| CN1972688B (zh) | 2004-05-06 | 2012-06-27 | 沃尼尔·朗伯有限责任公司 | 4-苯胺基-喹唑啉-6-基-酰胺类化合物 |
| PT1928409E (pt) * | 2005-09-12 | 2012-11-27 | Actelion Pharmaceuticals Ltd | Composição farmacêutica estável que compreende uma pirimidina-sulfamida |
| KR20120038021A (ko) | 2006-10-27 | 2012-04-20 | 화이자 프로덕츠 인코포레이티드 | 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법 |
| KR20160083132A (ko) * | 2007-06-06 | 2016-07-11 | 바스프 에스이 | 급속 붕해 정제의 제조를 위한 제약 제제 |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| BRPI1015941A2 (pt) * | 2009-07-02 | 2016-04-19 | Wyeth Llc | formulações de comprimido de 3-cianoquinolina e uso das mesmas. |
| SG10201500152UA (en) * | 2009-12-22 | 2015-03-30 | Abbvie Inc | Abt-263 capsule |
| JP4574742B1 (ja) * | 2010-04-08 | 2010-11-04 | 有限会社ミールジャパン | プロポリス組成物 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| TWI620736B (zh) | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ-２抑制劑之治療方法 |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| US8395552B2 (en) | 2010-11-23 | 2013-03-12 | Metamagnetics, Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
| CN102631347B (zh) * | 2012-05-03 | 2014-06-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种吉非替尼药物组合物及其制备方法 |
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR101332829B1 (ko) * | 2013-05-31 | 2013-11-27 | 재단법인 통합의료진흥원 | 보중익기탕을 포함하는 폐암 치료용 조성물 |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| KR101721831B1 (ko) * | 2014-11-06 | 2017-03-31 | 주식회사 종근당 | 로베글리타존을 함유하는 경구 투여용 약제학적 조성물 |
| WO2016096999A1 (en) | 2014-12-19 | 2016-06-23 | Synthon B.V. | Pharmaceutical composition comprising gefifinib |
| TWI744224B (zh) * | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| KR101739731B1 (ko) * | 2015-12-31 | 2017-05-25 | 환인제약 주식회사 | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 |
| JP6739289B2 (ja) * | 2016-08-25 | 2020-08-12 | 日本化薬株式会社 | ゲフィチニブを有効成分とする医薬錠剤の製造方法 |
| MA46361A (fr) | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
| CN108096251B (zh) * | 2016-11-24 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吉非替尼药物组合物及其制备方法 |
| CN107007562B (zh) * | 2017-02-16 | 2020-10-27 | 南京优科制药有限公司 | 一种吉非替尼片剂及其制备方法 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
| US4178376A (en) * | 1977-01-21 | 1979-12-11 | Interx Research Corporation | Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials |
| US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9207988D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Topical composition |
| EP0716597A1 (en) * | 1993-08-30 | 1996-06-19 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB2306885B (en) * | 1995-11-08 | 1999-07-14 | Reckitt & Colmann Prod Ltd | Supersaturated Pharmaceutical Compositions |
| JP4713698B2 (ja) * | 1997-03-05 | 2011-06-29 | スージェン， インク． | 疎水性薬剤の処方 |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| CA2359945C (en) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| ES2342660T3 (es) * | 2002-02-26 | 2010-07-12 | Astrazeneca Ab | Nuevas formas cristalinas del compuesto anticancerigeno zd1839. |
| KR20050104152A (ko) | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
-
2003
- 2003-02-24 KR KR1020107016079A patent/KR20100090726A/ko not_active Ceased
- 2003-02-24 PL PL372215A patent/PL208114B1/pl unknown
- 2003-02-24 MX MXPA04008307A patent/MXPA04008307A/es active IP Right Grant
- 2003-02-24 PT PT03706732T patent/PT1480679E/pt unknown
- 2003-02-24 AT AT03706732T patent/ATE362771T1/de active
- 2003-02-24 US US10/505,231 patent/US20050163835A1/en not_active Abandoned
- 2003-02-24 CN CNB038046164A patent/CN1326569C/zh not_active Expired - Lifetime
- 2003-02-24 AU AU2003208444A patent/AU2003208444B2/en not_active Expired
- 2003-02-24 UA UA20040907788A patent/UA76325C2/uk unknown
- 2003-02-24 EP EP03706732A patent/EP1480679B1/en not_active Expired - Lifetime
- 2003-02-24 KR KR1020047013177A patent/KR101002374B1/ko not_active Expired - Lifetime
- 2003-02-24 MY MYPI20030631A patent/MY135609A/en unknown
- 2003-02-24 CA CA2476587A patent/CA2476587C/en not_active Expired - Fee Related
- 2003-02-24 ES ES03706732T patent/ES2286406T3/es not_active Expired - Lifetime
- 2003-02-24 BR BRPI0307786A patent/BRPI0307786B8/pt not_active IP Right Cessation
- 2003-02-24 RU RU2004129280/15A patent/RU2318518C2/ru active
- 2003-02-24 JP JP2003570883A patent/JP4544863B2/ja not_active Expired - Lifetime
- 2003-02-24 NZ NZ534513A patent/NZ534513A/en not_active IP Right Cessation
- 2003-02-24 IL IL16364203A patent/IL163642A0/xx active IP Right Grant
- 2003-02-24 DK DK03706732T patent/DK1480679T3/da active
- 2003-02-24 WO PCT/GB2003/000803 patent/WO2003072139A1/en not_active Ceased
- 2003-02-24 DE DE60313956T patent/DE60313956T2/de not_active Expired - Lifetime
- 2003-02-25 TW TW092103905A patent/TWI271193B/zh not_active IP Right Cessation
- 2003-02-26 UY UY27682A patent/UY27682A1/es not_active Application Discontinuation
- 2003-02-26 AR ARP030100636A patent/AR038848A1/es not_active Application Discontinuation
- 2003-03-16 SA SA03240043A patent/SA03240043B1/ar unknown
-
2004
- 2004-08-19 IL IL163642A patent/IL163642A/en unknown
- 2004-08-24 IS IS7420A patent/IS2462B/is unknown
- 2004-08-24 CO CO04082661A patent/CO5601038A2/es not_active Application Discontinuation
- 2004-09-15 NO NO20043866A patent/NO328658B1/no not_active IP Right Cessation
-
2007
- 2007-07-20 CY CY20071100974T patent/CY1108026T1/el unknown
-
2008
- 2008-09-19 US US12/234,321 patent/US20090186890A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523293A5 (https=) | ||
| CA2476587A1 (en) | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative | |
| KR101892788B1 (ko) | 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도 | |
| CN104220068B (zh) | 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 | |
| JP2014532638A5 (https=) | ||
| MX2009002031A (es) | Sistema de liberacion controlada y metodo para fabricarlo. | |
| JP2015164965A (ja) | フリバンセリンの製剤及びその製造方法 | |
| EP2205279B1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| JP2009528322A (ja) | フリバンセリンによる弁膜性心疾患の治療又は予防 | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| EP2496217B1 (en) | Direct compression tablets of otilonium | |
| US20150335609A1 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| AU2014374259A1 (en) | Novel compositions | |
| JP2020525436A5 (https=) | ||
| TW201545745A (zh) | 阿利沙坦酯固體分散體及藥物組合物 | |
| JP2007500176A5 (https=) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| EP3976014A1 (en) | A combination comprising alogliptin and metformin | |
| WO2019142207A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
| RU2019144196A (ru) | Фармацевтическая композиция, содержащая ремоглифлозин и противодиабетическое средство | |
| JP2015503555A (ja) | ボセンタン制御放出性経口製剤 | |
| ES2323570T3 (es) | Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina. | |
| KR20130071430A (ko) | 둘록세틴의 경구 약제학적 조성물 | |
| CN116211859A (zh) | 一种含有马来酸奈拉替尼的药用组合物及其制备方法 | |
| RU2412706C1 (ru) | Лекарственная форма триметазидина дигидрохлорида с модифицированным высвобождением |